Loading...

Bernd Schnabl

TitleAssociate Professor In Residence
InstitutionUniversity of California San Diego
DepartmentMedicine
Address9500 Gilman Drive #0063
La Jolla CA 92093
Phone858-822-5311
vCardDownload vCard

    Collapse Research 
    Collapse Research Activities and Funding
    The Role of the Intestinal Mycobiome in Alcoholic Liver Disease
    NIH/NIAAA R01AA024726Apr 10, 2017 - Mar 31, 2022
    Role: Principal Investigator
    The Role of the Intestinal Mycobiome in Alcoholic Liver Disease
    NIH/NIAAA U01AA024726Apr 10, 2017 - Mar 31, 2022
    Role: Principal Investigator
    The Commensal Microflora Suppresses Liver Fibrosis
    VA I01BX002213Oct 1, 2014 - Sep 30, 2018
    Role: Principal Investigator
    Microbiome as Therapeutic Target in Alcoholic Hepatitis
    NIH/NIAAA U01AA021856Jun 1, 2013 - May 31, 2018
    Role: Principal Investigator
    Microbiome and intestinal innate immune response in alcoholic liver disease
    NIH/NIAAA R01AA020703Sep 25, 2011 - Jun 30, 2021
    Role: Principal Investigator
    Blocking toll-like receptor 4 signaling as therapy in hepatic fibrosis
    NIH/NIDDK K08DK081830Sep 30, 2009 - Jun 30, 2014
    Role: Principal Investigator

    Collapse ORNG Applications 
    Collapse Websites

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Tripathi A, Debelius J, Brenner DA, Karin M, Loomba R, Schnabl B, Knight R. Publisher Correction: The gut-liver axis and the intersection with the microbiome. Nat Rev Gastroenterol Hepatol. 2018 May 21. PMID: 29785003.
      View in: PubMed
    2. Tripathi A, Debelius J, Brenner DA, Karin M, Loomba R, Schnabl B, Knight R. The gut-liver axis and the intersection with the microbiome. Nat Rev Gastroenterol Hepatol. 2018 May 10. PMID: 29748586.
      View in: PubMed
    3. Ouyang X, Han SN, Zhang JY, Dioletis E, Nemeth BT, Pacher P, Feng D, Bataller R, Cabezas J, Stärkel P, Caballeria J, LePine Pongratz R, Cai SY, Schnabl B, Hoque R, Chen Y, Yang WH, Garcia-Martinez I, Wang FS, Gao B, Torok NJ, Kibbey RG, Mehal WZ. Digoxin Suppresses Pyruvate Kinase M2-Promoted HIF-1a Transactivation in Steatohepatitis. Cell Metab. 2018 May 01; 27(5):1156. PMID: 29719229.
      View in: PubMed
    4. Chen Y, Ouyang X, Hoque R, Garcia-Martinez I, Yousaf MN, Tonack S, Offermanns S, Dubuquoy L, Louvet A, Mathurin P, Massey V, Schnabl B, Bataller RA, Mehal WZ. B-hydroxybutyrate protects from alcohol-induced liver injury via a Hcar2-cAMP dependent pathway. J Hepatol. 2018 Apr 26. PMID: 29705237.
      View in: PubMed
    5. Brandl K, Hartmann P, Jih LJ, Pizzo DP, Argemi J, Ventura-Cots M, Coulter S, Liddle C, Ling L, Rossi SJ, DePaoli AM, Loomba R, Mehal WZ, Fouts DE, Lucey MR, Bosques-Padilla F, Mathurin P, Louvet A, Garcia-Tsao G, Verna EC, Abraldes JG, Brown RS, Vargas V, Altamirano J, Caballería J, Shawcross D, Stärkel P, Ho SB, Bataller R, Schnabl B. Dysregulation of serum bile acids and FGF19 in alcoholic hepatitis. J Hepatol. 2018 Apr 11. PMID: 29654817.
      View in: PubMed
    6. Caussy C, Hsu C, Lo MT, Liu A, Bettencourt R, Ajmera VH, Bassirian S, Hooker J, Sy E, Richards L, Schork N, Schnabl B, Brenner DA, Sirlin CB, Chen CH, Loomba R. Novel link between gut-microbiome derived metabolite and shared gene-effects with hepatic steatosis and fibrosis in NAFLD. Hepatology. 2018 Mar 23. PMID: 29572891.
      View in: PubMed
    7. Gong S, Lan T, Zeng L, Luo H, Yang X, Li N, Chen X, Liu Z, Li R, Win S, Liu S, Zhou H, Schnabl B, Jiang Y, Kaplowitz N, Chen P. Gut microbiota mediates diurnal variation of acetaminophen induced acute liver injury in mice. J Hepatol. 2018 Mar 08. PMID: 29524531.
      View in: PubMed
    8. Bluemel S, Wang L, Martino C, Lee S, Wang Y, Williams B, Horvath A, Stadlbauer V, Zengler K, Schnabl B. The Role of Intestinal C-type Regenerating Islet Derived-3 Lectins for Nonalcoholic Steatohepatitis. Hepatol Commun. 2018 Apr; 2(4):393-406. PMID: 29619418.
      View in: PubMed
    9. Khanova E, Wu R, Wang W, Yan R, Chen Y, French SW, Llorente C, Pan SQ, Yang Q, Li Y, Lazaro R, Ansong C, Smith RD, Bataller R, Morgan T, Schnabl B, Tsukamoto H. Pyroptosis by caspase11/4-gasdermin-D pathway in alcoholic hepatitis in mice and patients. Hepatology. 2018 May; 67(5):1737-1753. PMID: 29108122.
      View in: PubMed
    10. Ouyang X, Han SN, Zhang JY, Dioletis E, Nemeth BT, Pacher P, Feng D, Bataller R, Cabezas J, Stärkel P, Caballeria J, Pongratz RL, Cai SY, Schnabl B, Hoque R, Chen Y, Yang WH, Garcia-Martinez I, Wang FS, Gao B, Torok NJ, Kibbey RG, Mehal WZ. Digoxin Suppresses Pyruvate Kinase M2-Promoted HIF-1a Transactivation in Steatohepatitis. Cell Metab. 2018 Feb 06; 27(2):339-350.e3. PMID: 29414684.
      View in: PubMed
    11. Hartmann P, Schnabl B. Risk factors for progression of and treatment options for NAFLD in children. Clin Liver Dis (Hoboken). 2018 Jan; 11(1):11-15. PMID: 29629177.
      View in: PubMed
    12. Stärkel P, Leclercq S, de Timary P, Schnabl B. Intestinal dysbiosis and permeability: the yin and yang in alcohol dependence and alcoholic liver disease. Clin Sci (Lond). 2018 Jan 31; 132(2):199-212. PMID: 29352076.
      View in: PubMed
    13. Wang W, Zhao J, Gui W, Sun D, Dai H, Xiao L, Chu H, Du F, Zhu Q, Schnabl B, Huang K, Yang L, Hou X. Tauroursodeoxycholic acid inhibits intestinal inflammation and barrier disruption in mice with non-alcoholic fatty liver disease. Br J Pharmacol. 2018 02; 175(3):469-484. PMID: 29139555.
      View in: PubMed
    14. Llorente C, Jepsen P, Inamine T, Wang L, Bluemel S, Wang HJ, Loomba R, Bajaj JS, Schubert ML, Sikaroodi M, Gillevet PM, Xu J, Kisseleva T, Ho SB, DePew J, Du X, Sørensen HT, Vilstrup H, Nelson KE, Brenner DA, Fouts DE, Schnabl B. Publisher Correction: Gastric acid suppression promotes alcoholic liver disease by inducing overgrowth of intestinal Enterococcus. Nat Commun. 2017 Dec 12; 8(1):2137. PMID: 29233961.
      View in: PubMed
    15. Hartmann P, Hochrath K, Horvath A, Chen P, Seebauer CT, Llorente C, Wang L, Alnouti Y, Fouts DE, Stärkel P, Loomba R, Coulter S, Liddle C, Yu RT, Ling L, Rossi SJ, DePaoli AM, Downes M, Evans RM, Brenner DA, Schnabl B. Modulation of the intestinal bile acid/farnesoid X receptor/fibroblast growth factor 15 axis improves alcoholic liver disease in mice. Hepatology. 2017 Nov 21. PMID: 29159825.
      View in: PubMed
    16. Hochrath K, Schnabl B. Check your microbiota when taking the drug. Hepatology. 2018 01; 67(1):18-20. PMID: 28782199.
      View in: PubMed
    17. Inamine T, Schnabl B. Immunoglobulin A and liver diseases. J Gastroenterol. 2017 Oct 26. PMID: 29075899.
      View in: PubMed
    18. Llorente C, Jepsen P, Inamine T, Wang L, Bluemel S, Wang HJ, Loomba R, Bajaj JS, Schubert ML, Sikaroodi M, Gillevet PM, Xu J, Kisseleva T, Ho SB, DePew J, Du X, Sørensen HT, Vilstrup H, Nelson KE, Brenner DA, Fouts DE, Schnabl B. Gastric acid suppression promotes alcoholic liver disease by inducing overgrowth of intestinal Enterococcus. Nat Commun. 2017 10 16; 8(1):837. PMID: 29038503.
      View in: PubMed
    19. Boule LA, Ju C, Agudelo M, Parira T, Cannon A, Davis B, Eby J, Cresci G, Samuelson DR, Shukla P, Alrefai WA, Sureshchandra S, Pandey SC, Schnabl B, Curtis BJ, Wyatt TA, Choudhry MA, Kovacs EJ. Summary of the 2016 Alcohol and Immunology Research Interest Group (AIRIG) meeting. Alcohol. 2018 02; 66:35-43. PMID: 29127885.
      View in: PubMed
    20. Hendrikx T, Schnabl B. Lamin Deficiency in the Liver Sets the Stage for Nonalcoholic Steatohepatitis Development in Males. Cell Mol Gastroenterol Hepatol. 2017 Nov; 4(3):441-442. PMID: 29062878.
      View in: PubMed
    21. Yang AM, Inamine T, Hochrath K, Chen P, Wang L, Llorente C, Bluemel S, Hartmann P, Xu J, Koyama Y, Kisseleva T, Torralba MG, Moncera K, Beeri K, Chen CS, Freese K, Hellerbrand C, Lee SM, Hoffman HM, Mehal WZ, Garcia-Tsao G, Mutlu EA, Keshavarzian A, Brown GD, Ho SB, Bataller R, Stärkel P, Fouts DE, Schnabl B. Intestinal fungi contribute to development of alcoholic liver disease. J Clin Invest. 2017 Jun 30; 127(7):2829-2841. PMID: 28530644.
      View in: PubMed
    22. Loomba R, Seguritan V, Li W, Long T, Klitgord N, Bhatt A, Dulai PS, Caussy C, Bettencourt R, Highlander SK, Jones MB, Sirlin CB, Schnabl B, Brinkac L, Schork N, Chen CH, Brenner DA, Biggs W, Yooseph S, Venter JC, Nelson KE. Gut Microbiome-Based Metagenomic Signature for Non-invasive Detection of Advanced Fibrosis in Human Nonalcoholic Fatty Liver Disease. Cell Metab. 2017 May 02; 25(5):1054-1062.e5. PMID: 28467925.
      View in: PubMed
    23. Brandl K, Schnabl B. Intestinal microbiota and nonalcoholic steatohepatitis. Curr Opin Gastroenterol. 2017 May; 33(3):128-133. PMID: 28257306.
      View in: PubMed
    24. Stärkel P, Schnabl B. Bidirectional Communication between Liver and Gut during Alcoholic Liver Disease. Semin Liver Dis. 2016 09; 36(4):331-339. PMID: 27997973.
      View in: PubMed
    25. Eguchi A, Lazaro RG, Wang J, Kim J, Povero D, Willliams B, Ho SB, Stärkel P, Schnabl B, Ohno-Machado L, Tsukamoto H, Feldstein AE. Extracellular vesicles released by hepatocytes from gastric infusion model of alcoholic liver disease contain a MicroRNA barcode that can be detected in blood. Hepatology. 2017 02; 65(2):475-490. PMID: 27639178.
      View in: PubMed
    26. Inamine T, Yang AM, Wang L, Lee KC, Llorente C, Schnabl B. Genetic Loss of Immunoglobulin A Does Not Influence Development of Alcoholic Steatohepatitis in Mice. Alcohol Clin Exp Res. 2016 Dec; 40(12):2604-2613. PMID: 27739086.
      View in: PubMed
    27. Patel NS, Hooker J, Gonzalez M, Bhatt A, Nguyen P, Ramirez K, Richards L, Rizo E, Hernandez C, Kisseleva T, Schnabl B, Brenner D, Sirlin CB, Loomba R. Weight Loss Decreases Magnetic Resonance Elastography Estimated Liver Stiffness in Nonalcoholic Fatty Liver Disease. Clin Gastroenterol Hepatol. 2017 Mar; 15(3):463-464. PMID: 27712981.
      View in: PubMed
    28. Bluemel S, Williams B, Knight R, Schnabl B. Precision medicine in alcoholic and nonalcoholic fatty liver disease via modulating the gut microbiota. Am J Physiol Gastrointest Liver Physiol. 2016 Dec 01; 311(6):G1018-G1036. PMID: 27686615.
      View in: PubMed
    29. Llorente C, Schnabl B. Fast-Track Clearance of Bacteria from the Liver. Cell Host Microbe. 2016 07 13; 20(1):1-2. PMID: 27414492.
      View in: PubMed
    30. Chen P, Miyamoto Y, Mazagova M, Lee KC, Eckmann L, Schnabl B. Microbiota and Alcoholic Liver Disease. Alcohol Clin Exp Res. 2016 08; 40(8):1791-2. PMID: 27364225.
      View in: PubMed
    31. Arroyo V, Moreau R, Kamath PS, Jalan R, Ginès P, Nevens F, Fernández J, To U, García-Tsao G, Schnabl B. Acute-on-chronic liver failure in cirrhosis. Nat Rev Dis Primers. 2016 06 09; 2:16041. PMID: 27277335.
      View in: PubMed
    32. Fuchs M, Schnabl B. Editors' Introduction to the NAFLD and NASH Special Issue. Dig Dis Sci. 2016 May; 61(5):1211-3. PMID: 27068170.
      View in: PubMed
    33. Schnabl B. Liver capsule: Mechanisms of alcoholic hepatitis. Hepatology. 2016 07; 64(1):276. PMID: 26867027.
      View in: PubMed
    34. Wang L, Fouts DE, Stärkel P, Hartmann P, Chen P, Llorente C, DePew J, Moncera K, Ho SB, Brenner DA, Hooper LV, Schnabl B. Intestinal REG3 Lectins Protect against Alcoholic Steatohepatitis by Reducing Mucosa-Associated Microbiota and Preventing Bacterial Translocation. Cell Host Microbe. 2016 Feb 10; 19(2):227-39. PMID: 26867181; PMCID: PMC4786170 [Available on 02/10/17].
    35. Nakamoto N, Schnabl B. Does the Intestinal Microbiota Explain Differences in the Epidemiology of Liver Disease between East and West? Inflamm Intest Dis. 2016 Apr; 1(1):3-8. PMID: 27243019.
      View in: PubMed
    36. Ho SB, Matheny ME, Schnabl B. Changes in Hospital Admissions and Mortality for Complications of Cirrhosis: Implications for Clinicians and Health Systems. Gut Liver. 2016 Jan; 10(1):8-9. PMID: 26696026; PMCID: PMC4694728.
    37. Hartmann P, Seebauer CT, Mazagova M, Horvath A, Wang L, Llorente C, Varki NM, Brandl K, Ho SB, Schnabl B. Deficiency of intestinal mucin-2 protects mice from diet-induced fatty liver disease and obesity. Am J Physiol Gastrointest Liver Physiol. 2016 Mar 01; 310(5):G310-22. PMID: 26702135; PMCID: PMC4773827 [Available on 03/01/17].
    38. Schnabl B, Farshchi-Heydari S, Loomba R, Mattrey RF, Hoh CK, Sirlin CB, Brenner DA, Behling CA, Vera DR. Staging of fibrosis in experimental non-alcoholic steatohepatitis by quantitative molecular imaging in rat models. Nucl Med Biol. 2016 Feb; 43(2):179-87. PMID: 26872443.
      View in: PubMed
    39. Chen P, Miyamoto Y, Mazagova M, Lee KC, Eckmann L, Schnabl B. Microbiota Protects Mice Against Acute Alcohol-Induced Liver Injury. Alcohol Clin Exp Res. 2015 Dec; 39(12):2313-23. PMID: 26556636; PMCID: PMC4712135 [Available on 12/01/16].
    40. Brenner DA, Paik YH, Schnabl B. Role of Gut Microbiota in Liver Disease. J Clin Gastroenterol. 2015 Nov-Dec; 49 Suppl 1:S25-7. PMID: 26447960; PMCID: PMC4602394 [Available on 11/01/16].
    41. Bernardi M, Moreau R, Angeli P, Schnabl B, Arroyo V. Mechanisms of decompensation and organ failure in cirrhosis: From peripheral arterial vasodilation to systemic inflammation hypothesis. J Hepatol. 2015 Nov; 63(5):1272-84. PMID: 26192220.
      View in: PubMed
    42. Brandl K, Schnabl B. Is intestinal inflammation linking dysbiosis to gut barrier dysfunction during liver disease? Expert Rev Gastroenterol Hepatol. 2015; 9(8):1069-76. PMID: 26088524; PMCID: PMC4828034.
    43. Hartmann P, Seebauer CT, Schnabl B. Alcoholic liver disease: the gut microbiome and liver cross talk. Alcohol Clin Exp Res. 2015 May; 39(5):763-75. PMID: 25872593; PMCID: PMC4402724.
    44. Llorente C, Schnabl B. The gut microbiota and liver disease. Cell Mol Gastroenterol Hepatol. 2015 May 01; 1(3):275-284. PMID: 26090511.
      View in: PubMed
    45. Arulanandan A, Ang B, Bettencourt R, Hooker J, Behling C, Lin GY, Valasek MA, Ix JH, Schnabl B, Sirlin CB, Loomba R. Association Between Quantity of Liver Fat and Cardiovascular Risk in Patients With Nonalcoholic Fatty Liver Disease Independent of Nonalcoholic Steatohepatitis. Clin Gastroenterol Hepatol. 2015 Aug; 13(8):1513-20.e1. PMID: 25661453.
      View in: PubMed
    46. Chen P, Stärkel P, Turner JR, Ho SB, Schnabl B. Dysbiosis-induced intestinal inflammation activates tumor necrosis factor receptor I and mediates alcoholic liver disease in mice. Hepatology. 2015 Mar; 61(3):883-94. PMID: 25251280.
      View in: PubMed
    47. Wang L, Llorente C, Hartmann P, Yang AM, Chen P, Schnabl B. Methods to determine intestinal permeability and bacterial translocation during liver disease. J Immunol Methods. 2015 Jun; 421:44-53. PMID: 25595554; PMCID: PMC4451427.
    48. Fang S, Suh JM, Reilly SM, Yu E, Osborn O, Lackey D, Yoshihara E, Perino A, Jacinto S, Lukasheva Y, Atkins AR, Khvat A, Schnabl B, Yu RT, Brenner DA, Coulter S, Liddle C, Schoonjans K, Olefsky JM, Saltiel AR, Downes M, Evans RM. Intestinal FXR agonism promotes adipose tissue browning and reduces obesity and insulin resistance. Nat Med. 2015 Feb; 21(2):159-65. PMID: 25559344; PMCID: PMC4320010.
    49. Mazagova M, Wang L, Anfora AT, Wissmueller M, Lesley SA, Miyamoto Y, Eckmann L, Dhungana S, Pathmasiri W, Sumner S, Westwater C, Brenner DA, Schnabl B. Commensal microbiota is hepatoprotective and prevents liver fibrosis in mice. FASEB J. 2015 Mar; 29(3):1043-55. PMID: 25466902; PMCID: PMC4422368.
    50. Chen P, Torralba M, Tan J, Embree M, Zengler K, Stärkel P, van Pijkeren JP, DePew J, Loomba R, Ho SB, Bajaj JS, Mutlu EA, Keshavarzian A, Tsukamoto H, Nelson KE, Fouts DE, Schnabl B. Supplementation of saturated long-chain fatty acids maintains intestinal eubiosis and reduces ethanol-induced liver injury in mice. Gastroenterology. 2015 Jan; 148(1):203-214.e16. PMID: 25239591.
      View in: PubMed
    51. Patel NS, Doycheva I, Peterson MR, Hooker J, Kisselva T, Schnabl B, Seki E, Sirlin CB, Loomba R. Effect of weight loss on magnetic resonance imaging estimation of liver fat and volume in patients with nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol. 2015 Mar; 13(3):561-568.e1. PMID: 25218667.
      View in: PubMed
    52. Schnabl B. The Microbiome and the Liver. Gastroenterol Hepatol (N Y). 2014 Aug; 10(8):519-521. PMID: 28845144.
      View in: PubMed
    53. Chen P, Schnabl B. Host-microbiome interactions in alcoholic liver disease. Gut Liver. 2014 May; 8(3):237-41. PMID: 24827618; PMCID: PMC4026639.
    54. Schnabl B. Transplanting a fibrogenic microbiota. Hepatology. 2014 May; 59(5):1660-1. PMID: 24676698.
      View in: PubMed
    55. Wang L, Hartmann P, Haimerl M, Bathena SP, Sjöwall C, Almer S, Alnouti Y, Hofmann AF, Schnabl B. Nod2 deficiency protects mice from cholestatic liver disease by increasing renal excretion of bile acids. J Hepatol. 2014 Jun; 60(6):1259-67. PMID: 24560660; PMCID: PMC4028388.
    56. Jalan R, Fernandez J, Wiest R, Schnabl B, Moreau R, Angeli P, Stadlbauer V, Gustot T, Bernardi M, Canton R, Albillos A, Lammert F, Wilmer A, Mookerjee R, Vila J, Garcia-Martinez R, Wendon J, Such J, Cordoba J, Sanyal A, Garcia-Tsao G, Arroyo V, Burroughs A, Ginès P. Bacterial infections in cirrhosis: a position statement based on the EASL Special Conference 2013. J Hepatol. 2014 Jun; 60(6):1310-24. PMID: 24530646.
      View in: PubMed
    57. Schnabl B, Brenner DA. Interactions between the intestinal microbiome and liver diseases. Gastroenterology. 2014 May; 146(6):1513-24. PMID: 24440671; PMCID: PMC3996054.
    58. Patel NS, Peterson MR, Lin GY, Feldstein A, Schnabl B, Bettencourt R, Seki E, Sirlin CB, Loomba R. Insulin Resistance Increases MRI-Estimated Pancreatic Fat in Nonalcoholic Fatty Liver Disease and Normal Controls. Gastroenterol Res Pract. 2013; 2013:498296. PMID: 24348536; PMCID: PMC3855930.
    59. Hartmann P, Chen P, Wang HJ, Wang L, McCole DF, Brandl K, Stärkel P, Belzer C, Hellerbrand C, Tsukamoto H, Ho SB, Schnabl B. Deficiency of intestinal mucin-2 ameliorates experimental alcoholic liver disease in mice. Hepatology. 2013 Jul; 58(1):108-19. PMID: 23408358; PMCID: PMC3695050.
    60. Schnabl B. Linking intestinal homeostasis and liver disease. Curr Opin Gastroenterol. 2013 May; 29(3):264-70. PMID: 23493073; PMCID: PMC4077188.
    61. Grivennikov SI, Wang K, Mucida D, Stewart CA, Schnabl B, Jauch D, Taniguchi K, Yu GY, Osterreicher CH, Hung KE, Datz C, Feng Y, Fearon ER, Oukka M, Tessarollo L, Coppola V, Yarovinsky F, Cheroutre H, Eckmann L, Trinchieri G, Karin M. Adenoma-linked barrier defects and microbial products drive IL-23/IL-17-mediated tumour growth. Nature. 2012 Nov 08; 491(7423):254-8. PMID: 23034650; PMCID: PMC3601659.
    62. Hartmann P, Chen WC, Schnabl B. The intestinal microbiome and the leaky gut as therapeutic targets in alcoholic liver disease. Front Physiol. 2012; 3:402. PMID: 23087650; PMCID: PMC3468817.
    63. Hartmann P, Haimerl M, Mazagova M, Brenner DA, Schnabl B. Toll-like receptor 2-mediated intestinal injury and enteric tumor necrosis factor receptor I contribute to liver fibrosis in mice. Gastroenterology. 2012 Nov; 143(5):1330-40.e1. PMID: 22841787.
      View in: PubMed
    64. Brandl K, Tomisato W, Li X, Neppl C, Pirie E, Falk W, Xia Y, Moresco EM, Baccala R, Theofilopoulos AN, Schnabl B, Beutler B. Yip1 domain family, member 6 (Yipf6) mutation induces spontaneous intestinal inflammation in mice. Proc Natl Acad Sci U S A. 2012 Jul 31; 109(31):12650-5. PMID: 22802641; PMCID: PMC3412000.
    65. Schnabl B, Brenner DA. Fibroblast growth factor inducible 14 as potential target in patients with alcoholic hepatitis. Gut. 2013 Mar; 62(3):335-6. PMID: 22717452; PMCID: PMC4077319.
    66. Brenner DA, Kisseleva T, Scholten D, Paik YH, Iwaisako K, Inokuchi S, Schnabl B, Seki E, De Minicis S, Oesterreicher C, Taura K. Origin of myofibroblasts in liver fibrosis. Fibrogenesis Tissue Repair. 2012; 5(Suppl 1):S17. PMID: 23259769; PMCID: PMC3368775.
    67. Yan AW, Schnabl B. Bacterial translocation and changes in the intestinal microbiome associated with alcoholic liver disease. World J Hepatol. 2012 Apr 27; 4(4):110-8. PMID: 22567183; PMCID: PMC3345535.
    68. Iwaisako K, Haimerl M, Paik YH, Taura K, Kodama Y, Sirlin C, Yu E, Yu RT, Downes M, Evans RM, Brenner DA, Schnabl B. Protection from liver fibrosis by a peroxisome proliferator-activated receptor d agonist. Proc Natl Acad Sci U S A. 2012 May 22; 109(21):E1369-76. PMID: 22538808; PMCID: PMC3361396.
    69. Fouts DE, Torralba M, Nelson KE, Brenner DA, Schnabl B. Bacterial translocation and changes in the intestinal microbiome in mouse models of liver disease. J Hepatol. 2012 Jun; 56(6):1283-92. PMID: 22326468; PMCID: PMC3357486.
    70. Seki E, Schnabl B. Role of innate immunity and the microbiota in liver fibrosis: crosstalk between the liver and gut. J Physiol. 2012 Feb 01; 590(3):447-58. PMID: 22124143; PMCID: PMC3379693.
    71. Schnabl B, Czech B, Valletta D, Weiss TS, Kirovski G, Hellerbrand C. Increased expression of zinc finger protein 267 in non-alcoholic fatty liver disease. Int J Clin Exp Pathol. 2011; 4(7):661-6. PMID: 22076166; PMCID: PMC3209606.
    72. Schnabl B, Valletta D, Kirovski G, Hellerbrand C. Zinc finger protein 267 is up-regulated in hepatocellular carcinoma and promotes tumor cell proliferation and migration. Exp Mol Pathol. 2011 Dec; 91(3):695-701. PMID: 21840307; PMCID: PMC3342774.
    73. Brenner DA, Seki E, Taura K, Kisseleva T, Deminicis S, Iwaisako K, Inokuchi S, Schnabl B, Oesterreicher CH, Paik YH, Miura K, Kodama Y. Non-alcoholic steatohepatitis-induced fibrosis: Toll-like receptors, reactive oxygen species and Jun N-terminal kinase. Hepatol Res. 2011 Jul; 41(7):683-6. PMID: 21711427; PMCID: PMC3341613.
    74. Paik YH, Iwaisako K, Seki E, Inokuchi S, Schnabl B, Osterreicher CH, Kisseleva T, Brenner DA. The nicotinamide adenine dinucleotide phosphate oxidase (NOX) homologues NOX1 and NOX2/gp91(phox) mediate hepatic fibrosis in mice. Hepatology. 2011 May; 53(5):1730-41. PMID: 21384410; PMCID: PMC3082608.
    75. Siggs OM, Schnabl B, Webb B, Beutler B. X-linked cholestasis in mouse due to mutations of the P4-ATPase ATP11C. Proc Natl Acad Sci U S A. 2011 May 10; 108(19):7890-5. PMID: 21518881; PMCID: PMC3093471.
    76. Tacke F, Zimmermann HW, Trautwein C, Schnabl B. CXCL5 plasma levels decrease in patients with chronic liver disease. J Gastroenterol Hepatol. 2011 Mar; 26(3):523-9. PMID: 21332547; PMCID: PMC3058722.
    77. Yan AW, Fouts DE, Brandl J, Stärkel P, Torralba M, Schott E, Tsukamoto H, Nelson KE, Brenner DA, Schnabl B. Enteric dysbiosis associated with a mouse model of alcoholic liver disease. Hepatology. 2011 Jan; 53(1):96-105. PMID: 21254165; PMCID: PMC3059122.
    78. Miura K, Kodama Y, Inokuchi S, Schnabl B, Aoyama T, Ohnishi H, Olefsky JM, Brenner DA, Seki E. Toll-like receptor 9 promotes steatohepatitis by induction of interleukin-1beta in mice. Gastroenterology. 2010 Jul; 139(1):323-34.e7. PMID: 20347818; PMCID: PMC4631262.
    79. Kodama Y, Kisseleva T, Iwaisako K, Miura K, Taura K, De Minicis S, Osterreicher CH, Schnabl B, Seki E, Brenner DA. c-Jun N-terminal kinase-1 from hematopoietic cells mediates progression from hepatic steatosis to steatohepatitis and fibrosis in mice. Gastroenterology. 2009 Oct; 137(4):1467-1477.e5. PMID: 19549522; PMCID: PMC2757473.
    80. Brandl K, Rutschmann S, Li X, Du X, Xiao N, Schnabl B, Brenner DA, Beutler B. Enhanced sensitivity to DSS colitis caused by a hypomorphic Mbtps1 mutation disrupting the ATF6-driven unfolded protein response. Proc Natl Acad Sci U S A. 2009 Mar 03; 106(9):3300-5. PMID: 19202076; PMCID: PMC2651297.
    81. Kodama Y, Taura K, Miura K, Schnabl B, Osawa Y, Brenner DA. Antiapoptotic effect of c-Jun N-terminal Kinase-1 through Mcl-1 stabilization in TNF-induced hepatocyte apoptosis. Gastroenterology. 2009 Apr; 136(4):1423-34. PMID: 19249395.
      View in: PubMed
    82. De Minicis S, Seki E, Oesterreicher C, Schnabl B, Schwabe RF, Brenner DA. Reduced nicotinamide adenine dinucleotide phosphate oxidase mediates fibrotic and inflammatory effects of leptin on hepatic stellate cells. Hepatology. 2008 Dec; 48(6):2016-26. PMID: 19025999.
      View in: PubMed
    83. Miura K, Taura K, Kodama Y, Schnabl B, Brenner DA. Hepatitis C virus-induced oxidative stress suppresses hepcidin expression through increased histone deacetylase activity. Hepatology. 2008 Nov; 48(5):1420-9. PMID: 18671304.
      View in: PubMed
    84. Gäbele E, Mühlbauer M, Dorn C, Weiss TS, Froh M, Schnabl B, Wiest R, Schölmerich J, Obermeier F, Hellerbrand C. Role of TLR9 in hepatic stellate cells and experimental liver fibrosis. Biochem Biophys Res Commun. 2008 Nov 14; 376(2):271-6. PMID: 18760996.
      View in: PubMed
    85. Brandl K, Plitas G, Mihu CN, Ubeda C, Jia T, Fleisher M, Schnabl B, DeMatteo RP, Pamer EG. Vancomycin-resistant enterococci exploit antibiotic-induced innate immune deficits. Nature. 2008 Oct 09; 455(7214):804-7. PMID: 18724361; PMCID: PMC2663337.
    86. Schnabl B, Brandl K, Fink M, Gross P, Taura K, Gäbele E, Hellerbrand C, Falk W. A TLR4/MD2 fusion protein inhibits LPS-induced pro-inflammatory signaling in hepatic stellate cells. Biochem Biophys Res Commun. 2008 Oct 17; 375(2):210-4. PMID: 18694726.
      View in: PubMed
    87. Schnabl B, Scholten D, Brenner DA. What is the potential role of antifibrotic agents for the treatment of liver disease? Nat Clin Pract Gastroenterol Hepatol. 2008 Sep; 5(9):496-7. PMID: 18628735.
      View in: PubMed
    88. Tacke F, Trautwein C, Yagmur E, Hellerbrand C, Wiest R, Brenner DA, Schnabl B. Up-regulated eotaxin plasma levels in chronic liver disease patients indicate hepatic inflammation, advanced fibrosis and adverse clinical course. J Gastroenterol Hepatol. 2007 Aug; 22(8):1256-64. PMID: 17688666.
      View in: PubMed
    89. Brandl K, Plitas G, Schnabl B, DeMatteo RP, Pamer EG. MyD88-mediated signals induce the bactericidal lectin RegIII gamma and protect mice against intestinal Listeria monocytogenes infection. J Exp Med. 2007 Aug 06; 204(8):1891-900. PMID: 17635956; PMCID: PMC2118673.
    90. Tacke F, Gäbele E, Bataille F, Schwabe RF, Hellerbrand C, Klebl F, Straub RH, Luedde T, Manns MP, Trautwein C, Brenner DA, Schölmerich J, Schnabl B. Bone morphogenetic protein 7 is elevated in patients with chronic liver disease and exerts fibrogenic effects on human hepatic stellate cells. Dig Dis Sci. 2007 Dec; 52(12):3404-15. PMID: 17415633.
      View in: PubMed
    91. Wiest R, Jurzik L, Moleda L, Froh M, Schnabl B, von Hörsten S, Schölmerich J, Straub RH. Enhanced Y1-receptor-mediated vasoconstrictive action of neuropeptide Y (NPY) in superior mesenteric arteries in portal hypertension. J Hepatol. 2006 Mar; 44(3):512-9. PMID: 16324766.
      View in: PubMed
    92. Schnabl B, Hu K, Mühlbauer M, Hellerbrand C, Stefanovic B, Brenner DA, Schölmerich J. Zinc finger protein 267 is up-regulated during the activation process of human hepatic stellate cells and functions as a negative transcriptional regulator of MMP-10. Biochem Biophys Res Commun. 2005 Sep 16; 335(1):87-96. PMID: 16054593.
      View in: PubMed
    93. Hu K, Fink M, Froh M, Gäbele E, Hellerbrand C, Mühlbauer M, Wiest R, Schölmerich J, Schnabl B. Characterization of the human zinc finger protein 267 promoter: essential role of nuclear factor Y. Biochim Biophys Acta. 2005 May 25; 1729(1):14-23. PMID: 15814297.
      View in: PubMed
    94. Schnabl B, Choi YH, Hagedorn CH, Bataller R. DNA microarrays and data mining to study hepatic fibrosis. Methods Mol Med. 2005; 117:359-69. PMID: 16118462.
      View in: PubMed
    95. Mühlbauer M, Weiss TS, Thasler WE, Gelbmann CM, Schnabl B, Schölmerich J, Hellerbrand C. LPS-mediated NFkappaB activation varies between activated human hepatic stellate cells from different donors. Biochem Biophys Res Commun. 2004 Dec 03; 325(1):191-7. PMID: 15522218.
      View in: PubMed
    96. Stefanovic B, Stefanovic L, Schnabl B, Bataller R, Brenner DA. TRAM2 protein interacts with endoplasmic reticulum Ca2+ pump Serca2b and is necessary for collagen type I synthesis. Mol Cell Biol. 2004 Feb; 24(4):1758-68. PMID: 14749390; PMCID: PMC344171.
    97. Kweon YO, Paik YH, Schnabl B, Qian T, Lemasters JJ, Brenner DA. Gliotoxin-mediated apoptosis of activated human hepatic stellate cells. J Hepatol. 2003 Jul; 39(1):38-46. PMID: 12821042.
      View in: PubMed
    98. Schnabl B, Purbeck CA, Choi YH, Hagedorn CH, Brenner D. Replicative senescence of activated human hepatic stellate cells is accompanied by a pronounced inflammatory but less fibrogenic phenotype. Hepatology. 2003 Mar; 37(3):653-64. PMID: 12601363.
      View in: PubMed
    99. Stefanovic B, Schnabl B, Brenner DA. Inhibition of collagen alpha 1(I) expression by the 5' stem-loop as a molecular decoy. J Biol Chem. 2002 May 17; 277(20):18229-37. PMID: 11889120.
      View in: PubMed
    100. Schnabl B, Choi YH, Olsen JC, Hagedorn CH, Brenner DA. Immortal activated human hepatic stellate cells generated by ectopic telomerase expression. Lab Invest. 2002 Mar; 82(3):323-33. PMID: 11896211.
      View in: PubMed